Cancer Treatment Centers of America: Clinical Trials
Learn More About This Topic: Chat with Us | Email Us
A Randomized Controlled Study of YONDELIS(R)(Trabectedin) or Dacarbazine for the treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated With an Anthracycline and Ifosfamide
Summary
This is a randomized, open label multicenter study comparing the safety and efficacy of Yondelis(R) (Trabectedin) with dacarbazine among adults with unresectable, locally advanced or metastatic liposarcoma or leiomyosarcoma who were previously treated with an anthracycline and ifosfamide. Eligible patients will be randomly assigned to either the Yondelis(R) or dacarbazine treatment groups in a 2:1 ratio. Study treatment occurs on Day 1 of each 21-day cycle. Yondelis(R) will be administered via 24-hour infusion. Dacarbazine will be administered via 20-minute infusion.
For More Information:
Please contact one of our Oncology Information Specialists at 1-800-615-3055 to learn more about this clinical trial. Oncology Information Specialists are available 24 hours a day, 7 days a week, 365 days a year.
